Chiesi Farmaceutici S.p.A to acquire Amryt Pharma and with it Filsuvez
Chiesi Farmaceutici S.p.A. an international, research-focused biopharmaceuticals and healthcare group, and Amryt Pharma Plc a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, announced that the companies have entered into a definitive agreement under which Chiesi will acquire Amryt (the “Transaction”)
The Transaction was unanimously approved by both Chiesi and Amryt Boards of Directors and is anticipated to close by the end of the first half of 2023, subject to the satisfaction of all closing conditions. Under the terms of the Transaction, Chiesi will purchase all outstanding shares of Amryt for a purchase price per American Depositary Share (“ADS”) of Amryt, which each represent 5 Amryt ordinary shares, of US$14.50 (or US$2.90 per ordinary share) in cash, plus Contingent Value Rights (“CVRs”) of up to US$2.50 per ADS (or up to US$0.50 per ordinary share) payable if certain milestones related to Amryt’s product Filsuvez are achieved. The total Transaction value implied by the Transaction at close is approximately US$1.25 billion
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
